Loading the session
Loading the session
Loading instrument
$19.75
−0.23%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 21:14 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
Closed at $19.80 on 4 Nov 2026: 0.3% below the 52-week high of $19.87 (26 Oct 2026) and 372.6% above the low of $4.19 (12 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
1 month: +101.4% (SPY −1.6%, XLV +13.5%). 3 months: +76.2% (SPY −0.4%, XLV +15.5%). 1 year: +204.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SLN, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 close of $19.80 was 42.8% above its 50-day average ($13.86) and 113.5% above its 200-day average ($9.27). It has closed above the 200-day for 102 sessions, since 11 Jun 2026. The 50-day average crossed above the 200-day on 22 Apr 2026, 136 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
The 14-session relative strength index closed at 79.1 on 4 Nov 2026, its 13th session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
4 Nov 2026 volume of 1.0M shares was 0.2× the average of the 30 sessions before it (4.3M), as the price rose 0.1%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
October 19, 2026
+125.58%November 19, 2024
−36.75%April 27, 2023
+34.08%